Skip to content
2000
image of MAPT Haplotype Variation and Alzheimer’s Disease Risk: A Narrative Review with Focus on the Jordanian Population

Abstract

Introduction

Genetic variations in the microtubule-associated protein tau (MAPT) gene play a central role in Alzheimer's disease (AD) pathogenesis. Two major MAPT haplotypes, H1 and H2, show differential associations with tau expression and AD risk. However, data from Middle Eastern populations remain limited, restricting our understanding of population-specific disease susceptibility patterns and therapeutic responses.

Methods

We conducted a comprehensive literature review using PubMed, Scopus, and Web of Science databases. Search terms included “MAPT haplotype,” “Alzheimer's disease,” “H1 H2,” “tau pathology,” and “pharmacogenetics.” We analyzed peer-reviewed articles published between 2000 and 2024, focusing on studies reporting haplotype frequencies, MAPT expression levels, APOE interactions, and clinical outcomes. This review synthesizes published data without generating new experimental results.

Results

The H1 haplotype consistently associates with increased MAPT expression, tau accumulation, and elevated AD risk, particularly in APOE ε4 noncarriers. Conversely, the H2 haplotype appears protective, correlating with reduced tau burden and slower cognitive decline. Notably, recent reports reveal significant overrepresentation of the H2 haplotype in the Jordanian population compared to European and East Asian cohorts, where H2 frequency is substantially lower or absent. This distinct genetic architecture suggests altered regional AD risk profiles.

Discussions

The elevated H2 frequency in Jordan represents a unique population-specific genetic signature that may influence regional AD susceptibility patterns. These findings challenge current risk models predominantly based on European populations and suggest the need for population-tailored approaches in neurodegenerative disease research. The naturally H2-enriched Jordanian cohort provides an exceptional opportunity to investigate protective mechanisms against tau pathology.

Conclusion

MAPT haplotype distributions show significant population variation with important implications for AD risk assessment and therapeutic targeting. The high H2 frequency in Jordan warrants integration into personalized medicine frameworks and population-specific disease models, potentially informing more effective regional prevention and treatment strategies.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cn/10.2174/011570159X371971250818110608
2025-09-10
2025-10-29

  • From This Site

    /content/journals/cn/10.2174/011570159X371971250818110608
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Al-Kuraishy H.M. Sulaiman G.M. Mohammed H.A. Mohammed S.G. Al-Gareeb A.I. Albuhadily A.K. Dawood R.A. Al Ali A. Abu-Alghayth M.H. Amyloid-β and heart failure in Alzheimer’s disease: The new vistas. Front. Med. 2025 12 1494101 10.3389/fmed.2025.1494101 39967593
    [Google Scholar]
  2. Sánchez-Juan P. Moreno S. de Rojas I. Hernández I. Valero S. Alegret M. Montrreal L. García G.P. Lage C. López-García S. Rodrííguez-Rodríguez E. Orellana A. Tárraga L. Boada M. Ruiz A. The MAPT H1 haplotype is a risk factor for Alzheimer’s disease in APOE ε4 non-carriers. Front. Aging Neurosci. 2019 11 327 10.3389/fnagi.2019.00327 31866851
    [Google Scholar]
  3. Babić L.M. Španić P.E. Willumsen N. Nikolac P.M. Pleić N. Zubčić K. Langer H.L. Vogrinc Ž. Boban M. Borovečki F. Zemunik T. de Silva R. Šimić G. Further validation of the association between MAPT haplotype-tagging polymorphisms and Alzheimer’s disease: Neuropsychological tests, cerebrospinal fluid biomarkers, and APOE genotype. Front. Mol. Neurosci. 2024 17 1456670 10.3389/fnmol.2024.1456670 39386049
    [Google Scholar]
  4. Pedicone C. Weitzman S.A. Renton A.E. Goate A.M. Unraveling the complex role of MAPT-containing H1 and H2 haplotypes in neurodegenerative diseases. Mol. Neurodegener. 2024 19 1 43 10.1186/s13024‑024‑00731‑x 38812061
    [Google Scholar]
  5. Wen P. Sun Z. Gou F. Wang J. Fan Q. Zhao D. Yang L. Oxidative stress and mitochondrial impairment: Key drivers in neurodegenerative disorders. Ageing Res. Rev. 2025 104 102667 10.1016/j.arr.2025.102667 39848408
    [Google Scholar]
  6. Raj T. Shulman J.M. Keenan B.T. Chibnik L.B. Evans D.A. Bennett D.A. Stranger B.E. De Jager P.L. Alzheimer disease susceptibility loci: Evidence for a protein network under natural selection. Am. J. Hum. Genet. 2012 90 4 720 726 10.1016/j.ajhg.2012.02.022 22482808
    [Google Scholar]
  7. Halliwell B. Understanding mechanisms of antioxidant action in health and disease. Nat. Rev. Mol. Cell Biol. 2024 25 1 13 33 10.1038/s41580‑023‑00645‑4 37714962
    [Google Scholar]
  8. Kuczyńska M. Jakubek P. Bartoszek A. More than just antioxidants: Redox-active components and mechanisms shaping redox signalling network. Antioxidants 2022 11 12 2403 10.3390/antiox11122403 36552611
    [Google Scholar]
  9. Alkaraki A.K. Abuelezz A.I. Khabour O.F. Peña J.A. Alfonso-Sánchez M.A. Altaany Z. Tau (MAPT) haplotypes in Jordan: New evidence on the Middle East as a melting-pot predating Neolithic migration. Ann. Hum. Biol. 2021 48 5 448 450 10.1080/03014460.2021.1983018 34538162
    [Google Scholar]
  10. Feng P. Ma Z. Yan J. Sun L. Wu N. Cheng L. Yan D. High-resolution population mapping by fusing remote sensing and social sensing data considering the spatial scale mismatch issue. Int. J. Digit. Earth 2025 18 1 2479863 10.1080/17538947.2025.2479863
    [Google Scholar]
  11. Cummings J. Lee G. Zhong K. Fonseca J. Taghva K. Alzheimer’s disease drug development pipeline. Alzheimers Dement. 2021 7 1 12179 10.1002/trc2.12179 34095440
    [Google Scholar]
  12. Di Maria E. Cammarata S. Parodi M.I. Borghi R. Benussi L. Galli M. Galimberti D. Ghidoni R. Gonella D. Novello C. Pollero V. Perroni L. Odetti P. Scarpini E. Binetti G. Tabaton, M. The H1 haplotype of the tau gene (MAPT) is associated with mild cognitive impairment. J. Alzheimers Dis. 2010 19 3 909 914 10.3233/JAD‑2010‑1285 20157246
    [Google Scholar]
  13. Smaili I. Hajjaj I. Razine R. Tibar H. Salmi A. Bouslam N. Moussa A. Regragui W. Bouhouche A. A specific diplotype H1j/H2 of the MAPT gene could be responsible for Parkinson’s disease with dementia. Case Rep. Genet. 2020 2020 1 5 10.1155/2020/8813344 33343949
    [Google Scholar]
  14. Canu E. Boccardi M. Ghidoni R. Benussi L. Testa C. Pievani M. Bonetti M. Binetti G. Frisoni G.B. H1 haplotype of the MAPT gene is associated with lower regional gray matter volume in healthy carriers. Eur. J. Hum. Genet. 2009 17 3 287 294 10.1038/ejhg.2008.185 18854867
    [Google Scholar]
  15. Tauber C.V. Schwarz S.C. Rösler T.W. Arzberger T. Gentleman S. Windl O. Krumbiegel M. Reis A. Ruf V.C. Herms J. Höglinger G.U. Different MAPT haplotypes influence expression of total MAPT in postmortem brain tissue. Acta Neuropathol. Commun. 2023 11 1 40 10.1186/s40478‑023‑01534‑9 36906636
    [Google Scholar]
  16. Jairani P.S. Aswathy P.M. Gopala S. Verghese J. Mathuranath P.S. Interaction with the MAPT H1H1 genotype increases dementia risk in apoe ε4 carriers in a population of southern india. dement geriatr cogn disord 2016 42 5-6 255 264 10.1159/000447446 27705964 2016
    [Google Scholar]
  17. Strang K.H. Golde T.E. Giasson B.I. MAPT mutations, tauopathy, and mechanisms of neurodegeneration. Lab. Invest. 2019 99 7 912 928 10.1038/s41374‑019‑0197‑x 30742061
    [Google Scholar]
  18. Zhang C.C. Zhu J.X. Wan Y. Tan L. Wang H.F. Yu J.T. Tan L. Meta-analysis of the association between variants in MAPT and neurodegenerative diseases. Oncotarget 2017 8 27 44994 45007 10.18632/oncotarget.16690 28402959
    [Google Scholar]
  19. Allen M. Kachadoorian M. Quicksall Z. Zou F. Chai H.S. Younkin C. Crook J.E. Pankratz V.S. Carrasquillo M.M. Krishnan S. Nguyen T. Ma L. Malphrus K. Lincoln S. Bisceglio G. Kolbert C.P. Jen J. Mukherjee S. Kauwe J.K. Crane P.K. Haines J.L. Mayeux R. Pericak-Vance M.A. Farrer L.A. Schellenberg G.D. Parisi J.E. Petersen R.C. Graff-Radford N.R. Dickson D.W. Younkin S.G. Ertekin-Taner N. Association of MAPT haplotypes with Alzheimer’s disease risk and MAPT brain gene expression levels. Alzheimers Res. Ther. 2014 6 4 39 10.1186/alzrt268 25324900
    [Google Scholar]
  20. Heckman M.G. Brennan R.R. Labbé C. Soto A.I. Koga S. DeTure M.A. Murray M.E. Petersen R.C. Boeve B.F. van Gerpen J.A. Uitti R.J. Wszolek Z.K. Rademakers R. Dickson D.W. Ross O.A. Association of MAPT subhaplotypes with risk of progressive supranuclear palsy and severity of tau pathology. JAMA Neurol. 2019 76 6 710 717 10.1001/jamaneurol.2019.0250 30882841
    [Google Scholar]
  21. Setó-Salvia N. Clarimón J. Pagonabarraga J. Pascual-Sedano B. Campolongo A. Combarros O. Mateo J.I. Regaña D. Martínez-Corral M. Marquié M. Alcolea D. Suárez-Calvet M. Molina-Porcel L. Dols O. Gómez-Isla T. Blesa R. Lleó A. Kulisevsky J. Dementia risk in Parkinson disease: Disentangling the role of MAPT haplotypes. Arch. Neurol. 2011 68 3 359 364 10.1001/archneurol.2011.17 21403021
    [Google Scholar]
  22. Gallagher J. Gochanour C. Caspell-Garcia C. Dobkin R.D. Aarsland D. Alcalay R.N. Barrett M.J. Chahine L. Chen-Plotkin A.S. Coffey C.S. Dahodwala N. Eberling J.L. Espay A.J. Leverenz J.B. Litvan I. Mamikonyan E. Morley J. Richard I.H. Rosenthal L. Siderowf A.D. Simuni T. York M.K. Willis A.W. Xie S.X. Weintraub D. Marek K. Tanner C. Simuni T. Siderowf A. Galasko D. Chahine L. Coffey C. Merchant K. Poston K. Dobkin R. Foroud T. Mollenhauer B. Weintraub D. Brown E. Kieburtz K. Tosun-Turgut D. Poewe W. Bressman S. Hamer J. James R. Riley E. Seibyl J. Shaw L. Standaert D. Mantri S. Dahodwala N. Schwarzschild M. Marras C. Fernandez H. Shoulson I. Rowbotham H. Norcliffe-Kaufmann L. Casalin P. Trenkwalder C. Sherer T. Chowdhury S. Frasier M. Eberling J. Kopil K. O’Grady A. Gibaldi J. McGuire Kuhl M. Kirsch L. Flagg E. McMahon B. Stanley C. Fabrizio K. Ecklund D. Huff T. Peters R. Fedler J. Heathers L. Hobbick C. Antonopoulos G. Caspell-Garcia C. Brumm M. Toga A. Crawford K. Singleton A. Montine T. Korell M. Schneider R. Chou K. Russell D. Factor S. Hogarth P. Hauser R. Saint-Hilaire M.H. Shprecher D. Brockmann K. Tai Y. Barone P. Isaacson S. Espay A. Martí M.J. Tolosa E. Hu S-C. Moukheiber E. Corvol J-C. Giladi N. Ruiz-Martinez J. Aasly J.O. Stefanis L. Marder K. Tarakad A. Mestre T. Videnovic A. Pahwa R. Lew M. Shill H. Amara A. Adler C. Leehey M. Riboldi G. McFarland N. Postuma R. Mari Z. Pavese N. Hu M. Brüggemann N. Klein C. Bloem B. Singh A. Stovall A. Festa J. Ramia L. Wakeman K. Williams K. Blair C. Specketer K. Willeke D. Mule J. Hilt E. Peacock S. Ribb K. Ainscough S. Pennente L. Brown J. Gruenwald C. Sommerfeld B. Kausar F. Garrido A. Raymond D. Croitoru I. Kristiansen A.G. Mejia-Santana H. Singh A. Nogo D. Reddie S. Murphy S. O’Brien L. Ramachandran A. Madhuri F. Freire D. Ismail F. Osgood T. Friedeck H. Frisendahl J. Liu Y. Romano C. Clark K. Rizer K. Carvalho S. Mosovsky S. Sulaiman F. Valent D. Lopes R. Torreliza M. Paz S. Foster V.K. Grümmer M. Burgler M. van Zundert S. Koros C. Razzaque J. Long-term dementia risk in Parkinson disease. Neurology 2024 103 5 209699 10.1212/WNL.0000000000209699 39110916
    [Google Scholar]
  23. Kouli A. Spindler L.R.B. Fryer T.D. Hong Y.T. Malpetti M. Aigbirhio F.I. White S.R. Camacho M. O’Brien J.T. Williams-Gray C.H. Neuroinflammation is linked to dementia risk in Parkinson’s disease. Brain 2024 147 3 923 935 10.1093/brain/awad322 37757857
    [Google Scholar]
  24. Ressler H.W. Humphrey J. Vialle R.A. Babrowicz B. Kandoi S. Raj T. Dickson D.W. Ertekin-Taner N. Crary J.F. Farrell K. MAPT haplotype-associated transcriptomic changes in progressive supranuclear palsy. Acta Neuropathol. Commun. 2024 12 1 135 10.1186/s40478‑024‑01839‑3 39154163
    [Google Scholar]
  25. Gibson L.L. Weintraub D. Lemmen R. Perera G. Chaudhuri K.R. Svenningsson P. Aarsland D. Risk of dementia in Parkinson’s disease: A systematic review and meta‐analysis. Mov. Disord. 2024 39 10 1697 1709 10.1002/mds.29918 39036849
    [Google Scholar]
  26. Tunold J.A. Geut H. Rozemuller J.M.A. Henriksen S.P. Toft M. van de Berg W.D.J. Pihlstrøm L. APOE And MAPT are associated with dementia in neuropathologically confirmed Parkinson’s disease. Front. Neurol. 2021 12 631145 10.3389/fneur.2021.631145 33613437
    [Google Scholar]
  27. Gozes I. Pathology: A selected view on the current status. Neurodegenerative Diseases: Integrative PPPM Approach as the Medicine of the Future. Dordrecht Springer 2013 69 92
    [Google Scholar]
  28. Jellinger K.A. Recent update on the heterogeneity of the Alzheimer’s disease spectrum. J. Neural Transm. 2022 129 1 1 24 10.1007/s00702‑021‑02449‑2 34919190
    [Google Scholar]
  29. Winder-Rhodes S.E. Hampshire A. Rowe J.B. Peelle J.E. Robbins T.W. Owen A.M. Barker R.A. Association between MAPT haplotype and memory function in patients with Parkinson’s disease and healthy aging individuals. Neurobiol. Aging 2015 36 3 1519 1528 10.1016/j.neurobiolaging.2014.12.006 25577413
    [Google Scholar]
  30. Almawi W.Y. Nemr R. Finan R.R. Saldhana F.L. Hajjej A. HLA-A, -B, -C, -DRB1 and -DQB1 allele and haplotype frequencies in Lebanese and their relatedness to neighboring and distant populations. BMC Genomics 2022 23 1 456 10.1186/s12864‑022‑08682‑7 35725365
    [Google Scholar]
  31. Baker E. Leonenko G. Schmidt K.M. Hill M. Myers A.J. Shoai M. de Rojas I. Tesi N. Holstege H. van der Flier W.M. Pijnenburg Y.A.L. Ruiz A. Hardy J. van der Lee S. Escott-Price V. What does heritability of Alzheimer’s disease represent? PLoS One 2023 18 4 0281440 10.1371/journal.pone.0281440 37115753
    [Google Scholar]
  32. Anttila V. Bulik-Sullivan B. Finucane H.K. Walters R.K. Bras J. Duncan L. Escott-Price V. Falcone G.J. Gormley P. Malik R. Patsopoulos N.A. Ripke S. Wei Z. Yu D. Lee P.H. Turley P. Grenier-Boley B. Chouraki V. Kamatani Y. Berr C. Letenneur L. Hannequin D. Amouyel P. Boland A. Deleuze J.F. Duron E. Vardarajan B.N. Reitz C. Goate A.M. Huentelman M.J. Kamboh M.I. Larson E.B. Rogaeva E. St George-Hyslop P. Hakonarson H. Kukull W.A. Farrer L.A. Barnes L.L. Beach T.G. Demirci F.Y. Head E. Hulette C.M. Jicha G.A. Kauwe J.S.K. Kaye J.A. Leverenz J.B. Levey A.I. Lieberman A.P. Pankratz V.S. Poon W.W. Quinn J.F. Saykin A.J. Schneider L.S. Smith A.G. Sonnen J.A. Stern R.A. Van Deerlin V.M. Van Eldik L.J. Harold D. Russo G. Rubinsztein D.C. Bayer A. Tsolaki M. Proitsi P. Fox N.C. Hampel H. Owen M.J. Mead S. Passmore P. Morgan K. Nöthen M.M. Schott J.M. Rossor M. Lupton M.K. Hoffmann P. Kornhuber J. Lawlor B. McQuillin A. Al-Chalabi A. Bis J.C. Ruiz A. Boada M. Seshadri S. Beiser A. Rice K. van der Lee S.J. De Jager P.L. Geschwind D.H. Riemenschneider M. Riedel-Heller S. Rotter J.I. Ransmayr G. Hyman B.T. Cruchaga C. Alegret M. Winsvold B. Palta P. Farh K-H. Cuenca-Leon E. Furlotte N. Kurth T. Ligthart L. Terwindt G.M. Freilinger T. Ran C. Gordon S.D. Borck G. Adams H.H.H. Lehtimäki T. Wedenoja J. Buring J.E. Schürks M. Hrafnsdottir M. Hottenga J-J. Penninx B. Artto V. Kaunisto M. Vepsäläinen S. Martin N.G. Montgomery G.W. Kurki M.I. Hämäläinen E. Huang H. Huang J. Sandor C. Webber C. Muller-Myhsok B. Schreiber S. Salomaa V. Loehrer E. Göbel H. Macaya A. Pozo-Rosich P. Hansen T. Werge T. Kaprio J. Metspalu A. Kubisch C. Ferrari M.D. Belin A.C. van den Maagdenberg A.M.J.M. Zwart J-A. Boomsma D. Eriksson N. Olesen J. Chasman D.I. Nyholt D.R. Anney R. Avbersek A. Baum L. Berkovic S. Bradfield J. Buono R.J. Catarino C.B. Cossette P. De Jonghe P. Depondt C. Dlugos D. Ferraro T.N. French J. Hjalgrim H. Jamnadas-Khoda J. Kälviäinen R. Kunz W.S. Lerche H. Leu C. Lindhout D. Lo W. Lowenstein D. McCormack M. Møller R.S. Molloy A. Ng P-W. Oliver K. Privitera M. Radtke R. Ruppert A-K. Sander T. Schachter S. Schankin C. Scheffer I. Schoch S. Sisodiya S.M. Smith P. Sperling M. Striano P. Surges R. Thomas G.N. Visscher F. Whelan C.D. Zara F. Heinzen E.L. Marson A. Becker F. Stroink H. Zimprich F. Gasser T. Gibbs R. Heutink P. Martinez M. Morris H.R. Sharma M. Ryten M. Mok K.Y. Pulit S. Bevan S. Holliday E. Attia J. Battey T. Boncoraglio G. Thijs V. Chen W-M. Mitchell B. Rothwell P. Sharma P. Sudlow C. Vicente A. Markus H. Kourkoulis C. Pera J. Raffeld M. Silliman S. Boraska Perica V. Thornton L.M. Huckins L.M. William Rayner N. Lewis C.M. Gratacos M. Rybakowski F. Keski-Rahkonen A. Raevuori A. Hudson J.I. Reichborn-Kjennerud T. Monteleone P. Karwautz A. Mannik K. Baker J.H. O’Toole J.K. Trace S.E. Davis O.S.P. Helder S.G. Ehrlich S. Herpertz-Dahlmann B. Danner U.N. van Elburg A.A. Clementi M. Forzan M. Docampo E. Lissowska J. Hauser J. Tortorella A. Maj M. Gonidakis F. Tziouvas K. Papezova H. Yilmaz Z. Wagner G. Cohen-Woods S. Herms S. Julià A. Rabionet R. Dick D.M. Ripatti S. Andreassen O.A. Espeseth T. Lundervold A.J. Steen V.M. Pinto D. Scherer S.W. Aschauer H. Schosser A. Alfredsson L. Padyukov L. Halmi K.A. Mitchell J. Strober M. Bergen A.W. Kaye W. Szatkiewicz J.P. Cormand B. Ramos-Quiroga J.A. Sánchez-Mora C. Ribasés M. Casas M. Hervas A. Arranz M.J. Haavik J. Zayats T. Johansson S. Williams N. Elia J. Dempfle A. Rothenberger A. Kuntsi J. Oades R.D. Banaschewski T. Franke B. Buitelaar J.K. Arias Vasquez A. Doyle A.E. Reif A. Lesch K-P. Freitag C. Rivero O. Palmason H. Romanos M. Langley K. Rietschel M. Witt S.H. Dalsgaard S. Børglum A.D. Waldman I. Wilmot B. Molly N. Bau C.H.D. Crosbie J. Schachar R. Loo S.K. McGough J.J. Grevet E.H. Medland S.E. Robinson E. Weiss L.A. Bacchelli E. Bailey A. Bal V. Battaglia A. Betancur C. Bolton P. Cantor R. Celestino-Soper P. Dawson G. De Rubeis S. Duque F. Green A. Klauck S.M. Leboyer M. Levitt P. Maestrini E. Mane S. De-Luca D.M. Parr J. Regan R. Reichenberg A. Sandin S. Vorstman J. Wassink T. Wijsman E. Cook E. Santangelo S. Delorme R. Rogé B. Magalhaes T. Arking D. Schulze T.G. Thompson R.C. Strohmaier J. Matthews K. Melle I. Morris D. Blackwood D. McIntosh A. Bergen S.E. Schalling M. Jamain S. Maaser A. Fischer S.B. Reinbold C.S. Fullerton J.M. Grigoroiu-Serbanescu M. Guzman-Parra J. Mayoral F. Schofield P.R. Cichon S. Mühleisen T.W. Degenhardt F. Schumacher J. Bauer M. Mitchell P.B. Gershon E.S. Rice J. Potash J.B. Zandi P.P. Craddock N. Ferrier I.N. Alda M. Rouleau G.A. Turecki G. Ophoff R. Pato C. Anjorin A. Stahl E. Leber M. Czerski P.M. Edenberg H.J. Cruceanu C. Jones I.R. Posthuma D. Andlauer T.F.M. Forstner A.J. Streit F. Baune B.T. Air T. Sinnamon G. Wray N.R. MacIntyre D.J. Porteous D. Homuth G. Rivera M. Grove J. Middeldorp C.M. Hickie I. Pergadia M. Mehta D. Smit J.H. Jansen R. de Geus E. Dunn E. Li Q.S. Nauck M. Schoevers R.A. Beekman A.T.F. Knowles J.A. Viktorin A. Arnold P. Barr C.L. Bedoya-Berrio G. Bienvenu O.J. Brentani H. Burton C. Camarena B. Cappi C. Cath D. Cavallini M. Cusi D. Darrow S. Denys D. Derks E.M. Dietrich A. Fernandez T. Figee M. Freimer N. Gerber G. Grados M. Greenberg E. Hanna G.L. Hartmann A. Hirschtritt M.E. Hoekstra P.J. Huang A. Huyser C. Illmann C. Jenike M. Kuperman S. Leventhal B. Lochner C. Lyon G.J. Macciardi F. Madruga-Garrido M. Malaty I.A. Maras A. McGrath L. Miguel E.C. Mir P. Nestadt G. Nicolini H. Okun M.S. Pakstis A. Paschou P. Piacentini J. Pittenger C. Plessen K. Ramensky V. Ramos E.M. Reus V. Richter M.A. Riddle M.A. Robertson M.M. Roessner V. Rosário M. Samuels J.F. Sandor P. Stein D.J. Tsetsos F. Van Nieuwerburgh F. Weatherall S. Wendland J.R. Wolanczyk T. Worbe Y. Zai G. Goes F.S. McLaughlin N. Nestadt P.S. Grabe H-J. Depienne C. Konkashbaev A. Lanzagorta N. Valencia-Duarte A. Bramon E. Buccola N. Cahn W. Cairns M. Chong S.A. Cohen D. Crespo-Facorro B. Crowley J. Davidson M. DeLisi L. Dinan T. Donohoe G. Drapeau E. Duan J. Haan L. Hougaard D. Karachanak-Yankova S. Khrunin A. Klovins J. Kučinskas V. Lee Chee Keong J. Limborska S. Loughland C. Lönnqvist J. Maher B. Mattheisen M. McDonald C. Murphy K.C. Murray R. Nenadic I. van Os J. Pantelis C. Pato M. Petryshen T. Quested D. Roussos P. Sanders A.R. Schall U. Schwab S.G. Sim K. So H-C. Stögmann E. Subramaniam M. Toncheva D. Waddington J. Walters J. Weiser M. Cheng W. Cloninger R. Curtis D. Gejman P.V. Henskens F. Mattingsdal M. Oh S-Y. Scott R. Webb B. Breen G. Churchhouse C. Bulik C.M. Daly M. Dichgans M. Faraone S.V. Guerreiro R. Holmans P. Kendler K.S. Koeleman B. Mathews C.A. Price A. Scharf J. Sklar P. Williams J. Wood N.W. Cotsapas C. Palotie A. Smoller J.W. Sullivan P. Rosand J. Corvin A. Neale B.M. Analysis of shared heritability in common disorders of the brain. Science 2018 360 6395 eaap8757 10.1126/science.aap8757 29930110
    [Google Scholar]
  33. Valenca G.T. Srivastava G.P. Oliveira-Filho J. White C.C. Yu L. Schneider J.A. Buchman A.S. Shulman J.M. Bennett D.A. De Jager P.L. The role of MAPT haplotype H2 and isoform 1N/4R in parkinsonism of older adults. PLoS One 2016 11 7 0157452 10.1371/journal.pone.0157452 27458716
    [Google Scholar]
  34. Pan Z. Xu S. Population genomics of East Asian ethnic groups. Hereditas 2020 157 1 49 10.1186/s41065‑020‑00162‑w 33292737
    [Google Scholar]
  35. Okunoye O. Ojo O.O. Abiodun O. Abubakar S. Achoru C. Adeniji O. Agabi O. Agulanna U. Akinyemi R. Ali M. Ani-Osheku I. Arigbodi O. Bello A. Erameh C. Farombi T. Fawale M. Imarhiagbe F. Iwuozo E. Komolafe M. Nwani P. Nwazor E. Nyandaiti Y. Obiabo Y. Odeniyi O. Odiase F. Ojini F. Onwuegbuzie G. Osaigbovo G. Osemwegie N. Oshinaike O. Otubogun F. Oyakhire S. Ozomma S. Samuel S. Taiwo F. Wahab K. Zubair Y. Hernandez D. Bandres-Ciga S. Blauwendraat C. Singleton A. Houlden H. Hardy J. Rizig M. Okubadejo N. MAPT allele and haplotype frequencies in Nigerian Africans: Population distribution and association with Parkinson’s disease risk and age at onset. Parkinsonism Relat. Disord. 2023 113 105517 10.1016/j.parkreldis.2023.105517 37467655
    [Google Scholar]
  36. Ghidoni R. Signorini S. Barbiero L. Sina E. Cominelli P. Villa A. Benussi L. Binetti G. The H2 MAPT haplotype is associated with familial frontotemporal dementia. Neurobiol. Dis. 2006 22 2 357 362 10.1016/j.nbd.2005.11.013 16410051
    [Google Scholar]
  37. Lappalainen T. Li Y.I. Ramachandran S. Gusev A. Genetic and molecular architecture of complex traits. Cell 2024 187 5 1059 1075 10.1016/j.cell.2024.01.023 38428388
    [Google Scholar]
  38. Cobb J.N. DeClerck G. Greenberg A. Clark R. McCouch S. Next-generation phenotyping: Requirements and strategies for enhancing our understanding of genotype–phenotype relationships and its relevance to crop improvement. Theor. Appl. Genet. 2013 126 4 867 887 10.1007/s00122‑013‑2066‑0 23471459
    [Google Scholar]
  39. Quan C. Lu H. Lu Y. Zhou G. Population-scale genotyping of structural variation in the era of long-read sequencing. Comput. Struct. Biotechnol. J. 2022 20 2639 2647 10.1016/j.csbj.2022.05.047 35685364
    [Google Scholar]
  40. Jackson R.J. Hyman B.T. Serrano-Pozo A. Multifaceted roles of APOE in Alzheimer disease. Nat. Rev. Neurol. 2024 20 8 457 474 10.1038/s41582‑024‑00988‑2 38906999
    [Google Scholar]
  41. Sampedro F. Marín-Lahoz J. Martínez-Horta S. Pagonabarraga J. Kulisevsky J. Early gray matter volume loss in MAPT H1H1 de Novo PD patients: A possible association with cognitive decline. Front. Neurol. 2018 9 394 10.3389/fneur.2018.00394 29899731
    [Google Scholar]
  42. Zhang Y. Wu K.M. Yang L. Dong Q. Yu J.T. Tauopathies: New perspectives and challenges. Mol. Neurodegener. 2022 17 1 28 10.1186/s13024‑022‑00533‑z 35392986
    [Google Scholar]
  43. Valentino R.R. Koga S. Walton R.L. Soto-Beasley A.I. Kouri N. DeTure M.A. Murray M.E. Johnson P.W. Petersen R.C. Boeve B.F. Uitti R.J. Wszolek Z.K. Dickson D.W. Ross O.A. Heckman M.G. MAPT subhaplotypes in corticobasal degeneration: Assessing associations with disease risk, severity of tau pathology, and clinical features. Acta Neuropathol. Commun. 2020 8 1 218 10.1186/s40478‑020‑01097‑z 33287913
    [Google Scholar]
  44. Leveille E. Ross O.A. Gan-Or Z. Tau and MAPT genetics in tauopathies and synucleinopathies. Parkinsonism Relat. Disord. 2021 90 142 154 10.1016/j.parkreldis.2021.09.008 34593302
    [Google Scholar]
  45. Wang H. Yang F. Zhang S. Xin R. Sun Y. Genetic and environmental factors in Alzheimer’s and Parkinson’s diseases and promising therapeutic intervention via fecal microbiota transplantation. NPJ Parkinsons Dis. 2021 7 1 70 10.1038/s41531‑021‑00213‑7 34381040
    [Google Scholar]
  46. Wu H.M. Goate A.M. O’Reilly P.F. Heterogeneous effects of genetic risk for Alzheimer’s disease on the phenome. Transl. Psychiatry 2021 11 1 406 10.1038/s41398‑021‑01518‑0 34301914
    [Google Scholar]
  47. Zhang J. Zhang Y. Wang J. Xia Y. Zhang J. Chen L. Recent advances in Alzheimer’s disease: Mechanisms, clinical trials and new drug development strategies. Signal Transduct. Target. Ther. 2024 9 1 211 10.1038/s41392‑024‑01911‑3 39174535
    [Google Scholar]
  48. Wade-Martins R. The MAPT locus—a genetic paradigm in disease susceptibility. Nat. Rev. Neurol. 2012 8 9 477 478 10.1038/nrneurol.2012.169 22940644
    [Google Scholar]
  49. Caillet-Boudin M.L. Buée L. Sergeant N. Lefebvre B. Regulation of human MAPT gene expression. Mol. Neurodegener. 2015 10 1 28 10.1186/s13024‑015‑0025‑8 26170022
    [Google Scholar]
  50. Samudra N. Lane-Donovan C. VandeVrede L. Boxer A.L. Tau pathology in neurodegenerative disease: Disease mechanisms and therapeutic avenues. J. Clin. Invest. 2023 133 12 168553 10.1172/JCI168553 37317972
    [Google Scholar]
  51. Zhang X. Wang J. Zhang Z. Ye K. Tau in neurodegenerative diseases: Molecular mechanisms, biomarkers, and therapeutic strategies. Transl. Neurodegener. 2024 13 1 40 10.1186/s40035‑024‑00429‑6 39107835
    [Google Scholar]
  52. Wang Y. Mandelkow E. Tau in physiology and pathology. Nat. Rev. Neurosci. 2016 17 1 22 35 10.1038/nrn.2015.1 26631930
    [Google Scholar]
  53. Yamazaki Y. Zhao N. Caulfield T.R. Liu C.C. Bu G. Apolipoprotein E and Alzheimer disease: Pathobiology and targeting strategies. Nat. Rev. Neurol. 2019 15 9 501 518 10.1038/s41582‑019‑0228‑7 31367008
    [Google Scholar]
  54. Johnson K.B. Wei W.Q. Weeraratne D. Frisse M.E. Misulis K. Rhee K. Zhao J. Snowdon J.L. Precision medicine, AI, and the future of personalized health care. Clin. Transl. Sci. 2021 14 1 86 93 10.1111/cts.12884 32961010
    [Google Scholar]
  55. Congdon E.E. Ji C. Tetlow A.M. Jiang Y. Sigurdsson E.M. Tau-targeting therapies for Alzheimer disease: Current status and future directions. Nat. Rev. Neurol. 2023 19 12 715 736 10.1038/s41582‑023‑00883‑2 37875627
    [Google Scholar]
  56. Wobst H.J. Denk F. Oliver P.L. Livieratos A. Taylor T.N. Knudsen M.H. Bengoa-Vergniory N. Bannerman D. Wade-Martins R. Increased 4R tau expression and behavioural changes in a novel MAPT-N296H genomic mouse model of tauopathy. Sci. Rep. 2017 7 1 43198 10.1038/srep43198 28233851
    [Google Scholar]
  57. Stingl J. Brockmöller J. Study designs in clinical pharmacogenetic and pharmacogenomic research. In: Pharmacogenomics. Lam Y-W.F. Cavallari L.H. San Diego Academic Press 2013 309 341
    [Google Scholar]
  58. Moaddeb J. Haga S.B. Pharmacogenetic testing: Current evidence of clinical utility. Ther. Adv. Drug Saf. 2013 4 4 155 169 10.1177/2042098613485595 24020014
    [Google Scholar]
  59. Virolainen S.J. VonHandorf A. Viel K.C.M.F. Weirauch M.T. Kottyan L.C. Gene-environment interactions and their impact on human health. Genes Immun. 2022 24 1 1 11 10.1038/s41435‑022‑00192‑6 36585519
    [Google Scholar]
  60. Loboda A. Damulewicz M. Pyza E. Jozkowicz A. Dulak J. Role of Nrf2/HO-1 system in development, oxidative stress response and diseases: An evolutionarily conserved mechanism. Cell. Mol. Life Sci. 2016 73 17 3221 3247 10.1007/s00018‑016‑2223‑0 27100828
    [Google Scholar]
  61. He F. Ru X. Wen T. NRF2, a transcription factor for stress response and beyond. Int. J. Mol. Sci. 2020 21 13 4777 10.3390/ijms21134777 32640524
    [Google Scholar]
  62. Ngo V. Duennwald M.L. Nrf2 and oxidative stress: A general overview of mechanisms and implications in human disease. Antioxidants 2022 11 12 2345 10.3390/antiox11122345 36552553
    [Google Scholar]
  63. Ventades N.G. de-la-Rua C. Hervella M. High frequency of mitochondrial haplogroups H and H2 in medieval individuals from the Cathedral of Santa María (Basque Country). Their contribution to the study of inflammatory arthropathies. J. Archaeol. Sci. Rep. 2023 47 103782 10.1016/j.jasrep.2022.103782
    [Google Scholar]
/content/journals/cn/10.2174/011570159X371971250818110608
Loading
MAPT Haplotype Variation and Alzheimer’s Disease Risk: A Narrative Review with Focus on the Jordanian Population
Bentham Science Publishers ; https://doi.org/10.2174/011570159X371971250818110608
/content/journals/cn/10.2174/011570159X371971250818110608
/content/journals/cn/10.2174/011570159X371971250818110608
Loading

Data & Media loading...


  • Article Type:     Review Article
Keywords: MAPT haplotypes ; H1 and H2 haplotypes ; tau protein ; neurodegeneration ; population genetics ; genetic risk modeling ; Jordan ; Alzheimer’s disease

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test